? RODENT CANCER MODELS SHARED RESOURCE The Rodent Cancer Models Shared Resource (RCM) provides Duke Cancer Institute (DCI) members a full service approach to the investigation of cancer biology, from the creation of rodent models through the testing of chemotherapeutics. To achieve that goal DCI?s RCM combined two primary services: the Cancer Center Isolation Facility (CCIF) and the Rodent Genetic Engineering Services Team (RGEST). CCIF is a 30,000 square foot, stand-alone rodent barrier facility located in the heart of the Duke biomedical campus operated by the Duke Division of Laboratory Animal Resources (DLAR) and dedicated to cancer research. The CCIF physical plant supports work with hazardous materials at biosafety level 2 (BSL2), recombinant DNA, chemotherapeutics, as well as the maintenance of immunosuppressed (outbred athymic nude mice and inbred Nod SCID gamma (NSG) mice) and specific pathogen-free (SPF) rodents. Occupying space in CCIF and in nearby facities, RGEST produces custom designed, genetically altered, transgenic and gene-targeted mice. RCM personnel assist DCI investigators who require assistance with breeding services, veterinary or diagnostic services, animal and experimental protocol development, inoculation or testing of cell lines, and guidance for conducting safe and efficient cancer biology research. CCIF also provides equipment and rodent housing space for the CCSG- supported Optical Molecular Imaging and Analysis (OMIA) shared resource. Recently, significant investments by the Duke School of Medicine have enabled upgrades to CCIF and RGEST equipment. In 2018, the RCM provided services to 78 investigators, 61% of whom were DCI members and who accounted for 94% of total usage and represented all 8 DCI Research Programs. Use of this shared resource by DCI Members contributed to 332 DCI publications over the project period, 103 of which were in high impact journals (Impact Factor>9), demonstrating the value of RCM services. The immediate and long-term objectives of the RCM are to continue to provide high-quality barrier facility services, low-cost, high-quality immunocompromised and SPF mice and genetically engineered animal models using cutting edge approaches, improve and upgrade services when possible, and to provide key expertise and services to DCI members studying cancer biology and developing new agents for treating or diagnosing human cancers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31
Abdi, Khadar; Kuo, Chay T (2018) Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev 32:740-741
Lu, Min; Sanderson, Sydney M; Zessin, Amelia et al. (2018) Exercise inhibits tumor growth and central carbon metabolism in patient-derived xenograft models of colorectal cancer. Cancer Metab 6:14
Qian, Danwen; Liu, Hongliang; Wang, Xiaomeng et al. (2018) Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer :
Ashcraft, Kathleen A; Choudhury, Kingshuk Roy; Birer, Sam R et al. (2018) Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion. Radiat Res 190:12-21
Ong, Cecilia T; Campbell, Brittany M; Thomas, Samantha M et al. (2018) Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Ann Surg Oncol 25:2249-2260
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408

Showing the most recent 10 out of 513 publications